ClinicalTrials.gg
CompletedNCT07535814VATAHTA-ACUTEUpdated Apr 17, 2026

Aldosterone Identifies a High-Risk Recurrent Phenotype in Severe Hypertension

An observational study in Acute Severe Hypertension, sponsored by School of Medicine. National University of Cuyo. Completed at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by School of Medicine. National University of Cuyo · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Hypertension with a site in Argentina — 12 open to participants now, 18 under way, 9 of them phase 3. Hypertension · Argentina.

Started
2022
with 2 others
Observational
6 of 74
3 open now
Registered
72nd of 74
by date
Lead sponsor
2 of 74
School of Medicine. National University of Cuyo

Among the 74 studies in Hypertension with a site in Argentina, this one is one of 3 that started in 2022, is one of 6 observational ones, and was the 72nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

12 of the 74 studies in Hypertension with a site in Argentina are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Hypertension with a site in Argentina, or all of them as a file.
02

Study summary

Acute severe hypertension is a common and heterogeneous clinical condition associated with significant short-term morbidity and health care utilization. Despite its frequency, underlying pathophysiological mechanisms remain poorly characterized, particularly regarding the role of aldosterone dysregulation beyond classical primary aldosteronism.

The VATAHTA Acute Study is an observational cohort study designed to evaluate the association between aldosterone levels, renin profiles, and clinical outcomes in patients presenting with acute severe hypertension requiring hospital admission. The study aims to characterize a potential spectrum of aldosterone dysregulation and its relationship with short-term clinical severity, including length of hospital stay, target organ damage, and cardiovascular events.

By integrating clinical, biochemical, and outcome data, this study seeks to improve the understanding of pathophysiological phenotypes in acute severe hypertension and identify potential targets for risk stratification and future therapeutic strategies.

Read the detailed description

Acute severe hypertension represents a frequent cause of emergency department visits and hospital admissions, yet its underlying biological heterogeneity is insufficiently understood. While classical secondary causes such as primary aldosteronism have been extensively studied, emerging evidence suggests that a broader continuum of aldosterone dysregulation may contribute to cardiovascular risk, even in the absence of overt endocrine hypertension.

The VATAHTA Acute Study is a multicenter observational cohort including adult patients admitted with acute severe hypertension, defined by markedly elevated blood pressure levels requiring hospital management. The study will systematically collect clinical characteristics, laboratory parameters-including plasma aldosterone, renin levels, and aldosterone-to-renin ratio-and treatment data at admission.

The primary objective is to evaluate the association between aldosterone levels and short-term clinical severity, assessed by length of hospital stay. Secondary objectives include the relationship between aldosterone profiles and target organ damage, biochemical alterations (such as potassium and renal function), and short-term cardiovascular outcomes, including major adverse cardiovascular events (MACE).

Multivariable analyses will be performed to determine whether aldosterone levels are independently associated with clinical severity after adjustment for relevant confounders, including blood pressure at admission, age, sex, renal function, and potassium levels. The study also aims to explore phenotypic patterns consistent with aldosterone dysregulation beyond classical definitions, potentially identifying clinically relevant subgroups.

This study is expected to provide novel insights into the pathophysiology of acute severe hypertension and contribute to improved risk stratification and personalized management strategies.

03

Conditions studied

  • Acute Severe Hypertension

Browse trials for

Keywords

  • Aldosterone; Acute Severe Hypertension; Cardiovascular Risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients admitted to hospital due to acute severe hypertension, identified from institutional databases. The study population includes individuals with available biochemical assessment of the renin-angiotensin-aldosterone system at admission, allowing evaluation of aldosterone-related pathophysiological phenotypes and their association with short-term clinical outcomes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged ≥18 years Hospital admission due to acute severe hypertension, defined as systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥120 mmHg requiring in-hospital management Availability of plasma aldosterone and renin measurements at hospital admission or within the first 24 hours Availability of key clinical and laboratory data, including blood pressure, renal function, and serum potassium levels

Exclusion criteria

Exclusion Criteria:

Pregnancy or hypertensive disorders of pregnancy Known secondary hypertension due to endocrine causes other than suspected aldosterone dysregulation (e.g., pheochromocytoma, Cushing syndrome) Patients receiving chronic dialysis Severe acute conditions likely to independently determine short-term outcomes (e.g., septic shock, major trauma) Missing key data required for primary outcome assessment (length of hospital stay) Prior inclusion in the study cohort

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (actual)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Length of hospital stay

    Length of hospital stay (LOS), measured in days, defined as the time from hospital admission to discharge, will be used as a marker of short-term clinical severity. The association between plasma aldosterone levels and LOS will be evaluated using multivariable models adjusted for relevant clinical and biochemical confounders.

    Time frame: rom hospital admission to discharge (index hospitalization), an average of 36 months

07

Study locations

1 site
  • Laura Grazini
    Godoy Cruz, Mendoza Province 5501, Argentina
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Dec 2025, 45 months.

Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's 45 months is close to that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2026
First posted
Apr 17, 2026
StartActual
Mar 1, 2022
Primary completionActual
Dec 20, 2025
CompletionActual
Apr 1, 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07535814
Lead sponsor
School of Medicine. National University of Cuyo
Collaborators
Hospiral Español de Mendoza
Responsible party
Nicolas Federico Renna (Associate Professor of Phisiopathology. School of Medicine. National University of Cuyo, School of Medicine. National University of Cuyo) — Principal investigator
First posted
Apr 17, 2026
Start date
Mar 1, 2022
Primary completion
Dec 20, 2025
Completion
Apr 1, 2026
Last update
Apr 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion